Psychopharmacology Algorithms (April)

Date of Issue: 04/01/2020 | Volume: 18 | Number: 4

Issue Links:Learning Objectives | Editorial Information

How do you choose a psych med? This issue explores that question in schizophrenia, bipolar, and depression. Plus, we include a review of the novel antipsychotic Nuplazid, and a counterintuitive finding about antipsychotics in delirium from the Annals of Internal Medicine.

In This Issue

Clinical Update

How to Choose an Antipsychotic in Schizophrenia

Topics: Antipsychotics | Aripiprazole | Cariprazine | Clozapine | Negative Symptoms | olanzapine | Psychopharmacology | Psychopharmacology Tips | Psychosis | Risperidone | Schizophrenia

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.

Read More
Expert Q&A

The Psychopharmacology Algorithm Project

Topics: Antidepressant Augmentation | Antidepressants | Antipsychotics | Bipolar Disorder | Bupropion | Depression | Depressive Disorder | Escitalopram | Lamictal | Lamotrigine | Lithium | Mood Stabilizers | olanzapine | Psychopharmacology | Psychopharmacology Tips | Wellbutrin

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.

Read More
Clinical Update

Nuplazid: Novel Mechanism, Modest Benefits

Topics: Dopamine | Geriatric Psychiatry | Neurology | Novel Medications | Nuplazid | Parkinson’s

Pimavanserin (Nuplazid) aims to treat psychosis without blocking dopamine. Though FDA-approved for psychosis associated with Parkinson’s disease, the drug is being tested in a host of other disorders: Depression, dementia, and sexual dysfunction.

Read More
Research Update

Antipsychotics Fall Short in Delirium

Topics: Dopamine | Geriatric Psychiatry | Neurology | Novel Medications | Nuplazid | Parkinson’s

Antipsychotics remain a mainstay of delirium treatment despite significant concerns about their safety and efficacy. A pair of reports recently evaluated the evidence on their use in delirium.

Read More
In Brief

Singulair and Suicide: FDA Strengthens Warning

After a rise of adverse psychiatric reports on montelukast (Singulair), an oral leukotriene inhibitor used for asthma and allergies, the FDA added a black box warning in March 2020 about mood and behavior changes including suicide.

Read More
CME Post-Test

CME Post-Test - Psychopharmacology Algorithms, TCPR, April 2020

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.

Read More